New immune cell engagers for cancer immunotherapy

IF 67.7 1区 医学 Q1 IMMUNOLOGY
Aurore Fenis, Olivier Demaria, Laurent Gauthier, Eric Vivier, Emilie Narni-Mancinelli
{"title":"New immune cell engagers for cancer immunotherapy","authors":"Aurore Fenis, Olivier Demaria, Laurent Gauthier, Eric Vivier, Emilie Narni-Mancinelli","doi":"10.1038/s41577-023-00982-7","DOIUrl":null,"url":null,"abstract":"There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers — antibodies engineered to redirect T cells to recognize and kill cancer cells — for the treatment of haematological malignancies. However, the field still faces several challenges to develop agents that are consistently effective in a majority of patients and cancer types, such as optimizing drug dose, overcoming treatment resistance and improving efficacy in solid tumours. A new generation of T cell-targeted molecules was developed to tackle these issues that are potentially more effective and safer. In addition, agents designed to engage the antitumour activities of other immune cells, including natural killer cells and myeloid cells, are showing promise and have the potential to treat a broader range of cancers. Immune cell engagers — antibody-based molecules engineered to direct immune effector cells to recognize and kill cancer cells — represent a rapidly expanding approach in cancer therapy. Here, the authors bring us up to date with the targets, challenges and opportunities for harnessing the anticancer activities of T cells, natural killer cells and myeloid cells with immune cell engagers.","PeriodicalId":19049,"journal":{"name":"Nature Reviews Immunology","volume":" ","pages":"471-486"},"PeriodicalIF":67.7000,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41577-023-00982-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers — antibodies engineered to redirect T cells to recognize and kill cancer cells — for the treatment of haematological malignancies. However, the field still faces several challenges to develop agents that are consistently effective in a majority of patients and cancer types, such as optimizing drug dose, overcoming treatment resistance and improving efficacy in solid tumours. A new generation of T cell-targeted molecules was developed to tackle these issues that are potentially more effective and safer. In addition, agents designed to engage the antitumour activities of other immune cells, including natural killer cells and myeloid cells, are showing promise and have the potential to treat a broader range of cancers. Immune cell engagers — antibody-based molecules engineered to direct immune effector cells to recognize and kill cancer cells — represent a rapidly expanding approach in cancer therapy. Here, the authors bring us up to date with the targets, challenges and opportunities for harnessing the anticancer activities of T cells, natural killer cells and myeloid cells with immune cell engagers.

Abstract Image

Abstract Image

Abstract Image

用于癌症免疫疗法的新型免疫细胞诱导剂。
近年来,癌症免疫疗法取得了重大进展,包括开发出治疗血液系统恶性肿瘤的 T 细胞吞噬剂(T 细胞吞噬剂是一种抗体,可引导 T 细胞识别并杀死癌细胞)。然而,要开发出对大多数患者和癌症类型持续有效的药物,该领域仍面临一些挑战,如优化药物剂量、克服耐药性和提高实体瘤的疗效。新一代 T 细胞靶向分子的开发就是为了解决这些问题,它们可能更有效、更安全。此外,旨在调动其他免疫细胞(包括自然杀伤细胞和类髓鞘细胞)抗肿瘤活性的药物也显示出良好的前景,有望治疗更广泛的癌症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Nature Reviews Immunology
Nature Reviews Immunology 医学-免疫学
CiteScore
93.40
自引率
0.40%
发文量
131
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Immunology is a journal that provides comprehensive coverage of all areas of immunology, including fundamental mechanisms and applied aspects. It has two international standard serial numbers (ISSN): 1474-1733 for print and 1474-1741 for online. In addition to review articles, the journal also features recent developments and new primary papers in the field, as well as reflections on influential people, papers, and events in the development of immunology. The subjects covered by Nature Reviews Immunology include allergy and asthma, autoimmunity, antigen processing and presentation, apoptosis and cell death, chemokines and chemokine receptors, cytokines and cytokine receptors, development and function of cells of the immune system, haematopoiesis, infection and immunity, immunotherapy, innate immunity, mucosal immunology and the microbiota, regulation of the immune response, signalling in the immune system, transplantation, tumour immunology and immunotherapy, and vaccine development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信